Abstract
Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Volume: 14 Issue: 1
Author(s): Sara Grammatico, Claudio Cartoni, Maria T. Petrucci, Pasquale Niscola, Marco Giovannini, Laura Scaramucci, Andrea Tendas, Adriana Costa, Marta Chisini, Gregorio A. Brunetti, Giada Mastrogiacomo, Sara Kiflom, Romina Talone, Giorgia Annechini, Ida Carmosino, Erminia Baldacci, Giacomo S. Morano and Giovanna Palumbo
Affiliation:
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Abstract: Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Export Options
About this article
Cite this article as:
Grammatico Sara, Cartoni Claudio, T. Petrucci Maria, Niscola Pasquale, Giovannini Marco, Scaramucci Laura, Tendas Andrea, Costa Adriana, Chisini Marta, A. Brunetti Gregorio, Mastrogiacomo Giada, Kiflom Sara, Talone Romina, Annechini Giorgia, Carmosino Ida, Baldacci Erminia, S. Morano Giacomo and Palumbo Giovanna, Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2016; 14 (1) . https://dx.doi.org/10.2174/1871525714666160405110833
DOI https://dx.doi.org/10.2174/1871525714666160405110833 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia
Current Molecular Medicine The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Cell Death Targeting Therapies in B Lymphoid Malignancies
Current Drug Targets The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia
Current Cancer Drug Targets Effect of Colestimide on Reduction of Body Weight and Waist Circumference in Metabolic Syndrome Patients with Cardiovascular Risk Factors
Vascular Disease Prevention (Discontinued) Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry